|
1A07
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-MALONYL TYR-GLU-(N,N-DIPENTYL AMINE)
Deposited 1997-12-09
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8;277 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M MES, PH 6.5, 0.05 M CSCL, 30% JEFFAMINE M-600 AT 4 DEGREES C., pH 8.0, temperature 277K
|
Resolution 2.20 Å
|
|
1A08
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
Deposited 1997-12-09
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;277 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2.1 M AMMONIUM SULFATE AT 4 C., temperature 277K
|
Resolution 2.20 Å
|
|
1A08
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-DIFLUORO PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
Deposited 1997-12-09
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;277 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2.1 M AMMONIUM SULFATE AT 4 C., temperature 277K
|
Resolution 2.20 Å
|
|
1A09
C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine)
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;277 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2 M NAFORMATE AT 4 C. THE CRYSTAL WAS SOAKED IN 10% PEG400, 10% GLYCEROL PRIOR TO DATA COLLECTION, temperature 277K
|
Resolution 2.00 Å
|
|
1A09
C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine)
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;277 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2 M NAFORMATE AT 4 C. THE CRYSTAL WAS SOAKED IN 10% PEG400, 10% GLYCEROL PRIOR TO DATA COLLECTION, temperature 277K
|
Resolution 2.00 Å
|
|
1A09
C-src (SH2 domain) complexed with ace-formyl phosphotyr-glu-(n,n-dipentyl amine)
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;277 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6, 2 M NAFORMATE AT 4 C. THE CRYSTAL WAS SOAKED IN 10% PEG400, 10% GLYCEROL PRIOR TO DATA COLLECTION, temperature 277K
|
Resolution 2.00 Å
|
|
1A1A
C-SRC (SH2 DOMAIN WITH C188A MUTATION) COMPLEXED WITH ACE-FORMYL PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Mutation:C188S
Mutation:C188S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8;277 K;PROTEIN WAS CRYSTALLIZED FROM 1.0 M LI2SO4, 2% PEG8000 AT 4C. THE CRYSTAL WAS SOAKED IN 25% GLYCEROL PRIOR TO DATA COLLECTION., pH 8.0, temperature 277K
|
Resolution 2.00 Å
|
|
1A1B
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N,N-DIPENTYL AMINE)
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8;277 K;PROTEIN WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE AT 4 DEGREES C., pH 8.0, temperature 277K
|
Resolution 2.20 Å
|
|
1A1C
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(N-ME(-(CH2)3-CYCLOPENTYL))
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 4.6;295 K;PROTEIN WAS CRYSTALLIZED FROM 0.1 M ACETATE, PH 4.6,2M AMMONIUM SULFATE AT 22 C., temperature 295K
|
Resolution 2.40 Å
|
|
1A1E
C-SRC (SH2 DOMAIN) COMPLEXED WITH ACE-PHOSPHOTYR-GLU-(3-BUTYLPIPERIDINE)
Deposited 1997-12-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 4
PDB declaration: tetrameric
|
Chain A
143–248(106 aa)
Fragment:SH2 DOMAIN
Chain B
143–248(106 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 8;295 K;PROTEIN WAS CRYSTALLIZED FROM 2M AMMONIUM SULFATE AT 22 DEGREES C., pH 8.0, temperature 295K
|
Resolution 2.20 Å
|
|
1FMK
CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC
Deposited 1997-01-24
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
85–535(451 aa)
Fragment:RESIDUES 86-836, CONTAINING SH2, SH3, KINASE 2 DOMAINS AND C-TERMINAL TAIL
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 1.50 Å
R-free 0.264
|
|
1HCS
NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEX
Deposited 1994-09-02
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
143–248(106 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
mmCIF provides none of the parsed conditions
|
Resolution not provided
|
|
1HCT
NMR STRUCTURE OF THE HUMAN SRC SH2 DOMAIN COMPLEX
Deposited 1994-09-02
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
143–248(106 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
mmCIF provides none of the parsed conditions
|
Resolution not provided
|
|
1KSW
Structure of Human c-Src Tyrosine Kinase (Thr338Gly Mutant) in Complex with N6-benzyl ADP
Deposited 2002-01-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
85–535(451 aa)
Fragment:SH3, SH2 and Kinase domains
|
Mutation:T338G
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
NBS N6-BENZYL ADENOSINE-5'-DIPHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;298 K;12% PEG 4000, 50mM PIPES pH 6.5, 10mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.80 Å
R-free 0.294
|
|
1O41
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78300.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
300 2-FORMYL-6-METHOXYPHENYL DIHYDROGEN PHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O42
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU81843.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
843 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-O-PHOSPHONOTYROSINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O43
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82129.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
821 [4-((1Z)-2-(ACETYLAMINO)-3-{[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]AMINO}-3-OXOPROP-1-ENYL)-2-FORMYLPHENYL]ACET IC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.50 Å
|
|
1O44
Crystal structure of sh2 in complex with ru85052
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
852 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXY-PHENYL}-MALONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O45
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU84687.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
687 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3-FORMYL-O-PHOSPHONOTYROSINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.80 Å
|
|
1O46
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU90395.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
903 2-{4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-METHOXYCARBONYL-PHENYL}-2-FLUORO-MALONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 2.00 Å
|
|
1O47
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82209.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
822 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-4-[DIFLUORO(PHOSPHONO)METHYL]PHENYLALANINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.80 Å
|
|
1O48
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85053.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
853 5-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-CARBOXYMETHYL-BENZOIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.55 Å
|
|
1O49
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU85493.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
493 {4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-PHOSPHONO-PHENOXY}-ACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O4A
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU82197.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
197 4-[2-ACETYLAMINO-2-(1-BIPHENYL-4-YLMETHYL-2-OXO-AZEPAN-3-YLCARBAMOYL)-ETHYL]-2-FORMYL-BENZOIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.50 Å
|
|
1O4B
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU83876.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
876 N-ACETYL-N-[1-(1,1'-BIPHENYL-4-YLMETHYL)-2-OXOAZEPAN-3-YL]-3,4-DIPHOSPHONOPHENYLALANINAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.85 Å
|
|
1O4C
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHOSPHATE.
Deposited 2003-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.80 Å
|
|
1O4D
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78262.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
262 2-FORMYLPHENYL DIHYDROGEN PHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.85 Å
|
|
1O4E
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78299.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
299 2,6-DIFORMYL-4-METHYLPHENYL DIHYDROGEN PHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 2.00 Å
|
|
1O4F
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79073.
Deposited 2003-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
790 1,2,3,4-TETRAHYDROQUINOLIN-8-YL DIHYDROGEN PHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 2.00 Å
|
|
1O4G
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH DPI59.
Deposited 2003-06-15
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
I59 HYDROXY(1-NAPHTHYL)METHYLPHOSPHONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.55 Å
|
|
1O4H
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79072.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
772 2-CYANOQUINOLIN-8-YL DIHYDROGEN PHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 2.25 Å
|
|
1O4I
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PAS219.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
219 cyclohexylmethyl 2-formylphenyl hydrogen (S)-phosphate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.75 Å
|
|
1O4J
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH ISO24.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
IS2 [(4-ETHYLPHENYL)AMINO]CARBONYLPHOSPHONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O4K
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PASBN.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
PSN BENZYL 2-FORMYLPHENYL HYDROGEN PHOSPHATE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.57 Å
|
|
1O4L
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH FRAGMENT2.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
CIT CITRIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.65 Å
|
|
1O4M
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH MALONICACID.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
MLA MALONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.60 Å
|
|
1O4N
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH OXALIC ACID.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
OXD OXALIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.60 Å
|
|
1O4O
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH PHENYLPHOSPHATE.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
HPS PHENYL DIHYDROGEN PHOSPHATE × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O4P
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78791.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
791 2-PHENYLMALONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.90 Å
|
|
1O4Q
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU79256.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
256 PHENYL(SULFO)ACETIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.70 Å
|
|
1O4R
CRYSTAL STRUCTURE OF SH2 IN COMPLEX WITH RU78783.
Deposited 2003-06-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–251(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
787 (PHENYL-PHOSPHONO-METHYL)-PHOSPHONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.5;pH 5.50
|
Resolution 1.50 Å
|
|
1SHD
PEPTIDE INHIBITORS OF SRC SH3-SH2-PHOSPHOPROTEIN INTERACTIONS
Deposited 1994-11-10
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
143–248(106 aa)
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.00 Å
|
|
1Y57
Structure of unphosphorylated c-Src in complex with an inhibitor
Deposited 2004-12-02
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
86–536(451 aa)
Fragment:SH3 SH2 and KINASE domains
|
Not recorded
|
SO4 SULFATE ION × 5
MPZ 4-[(4-METHYLPIPERAZIN-1-YL)METHYL]-N-{3-[(4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO]PHENYL}BENZAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;293 K;ammonium sulfate, tris, glycerol, pH 8.0, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 1.91 Å
R-free 0.213
|
|
1YI6
C-term tail segment of human tyrosine kinase (258-533)
Deposited 2005-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
260–535(276 aa)
Fragment:residues 258-533
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;PEG 6000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.252
|
|
1YI6
C-term tail segment of human tyrosine kinase (258-533)
Deposited 2005-01-11
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
260–535(276 aa)
Fragment:residues 258-533
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;PEG 6000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 293K
|
Resolution 2.00 Å
R-free 0.252
|
|
1YOJ
Crystal structure of Src kinase domain
Deposited 2005-01-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
253–535(283 aa)
Fragment:Src kinase domain
|
Mutation:S344N, A369S, Y418W
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;297 K;20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 1.95 Å
R-free 0.258
|
|
1YOJ
Crystal structure of Src kinase domain
Deposited 2005-01-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
253–535(283 aa)
Fragment:Src kinase domain
|
Mutation:S344N, A369S, Y418W
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;297 K;20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 1.95 Å
R-free 0.258
|
|
1YOL
Crystal structure of Src kinase domain in complex with CGP77675
Deposited 2005-01-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
253–535(283 aa)
Fragment:SRC KINASE DOMAIN
|
Mutation:S344N, A369S
|
S03 1-{4-[4-AMINO-5-(3-METHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL]BENZYL}PIPERIDIN-4-OL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;297 K;20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.30 Å
R-free 0.247
|
|
1YOL
Crystal structure of Src kinase domain in complex with CGP77675
Deposited 2005-01-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
253–535(283 aa)
Fragment:SRC KINASE DOMAIN
|
Mutation:S344N, A369S
|
S03 1-{4-[4-AMINO-5-(3-METHOXYPHENYL)-7H-PYRROLO[2,3-D]PYRIMIDIN-7-YL]BENZYL}PIPERIDIN-4-OL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;297 K;20% ethylene glycol, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.30 Å
R-free 0.247
|
|
1YOM
Crystal structure of Src kinase domain in complex with Purvalanol A
Deposited 2005-01-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
253–535(283 aa)
Fragment:Src kinase domain
|
Mutation:S344N, A369S, Y418W
|
P01 2-({6-[(3-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;297 K;20% ethylene glycol , pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.90 Å
R-free 0.313
|
|
1YOM
Crystal structure of Src kinase domain in complex with Purvalanol A
Deposited 2005-01-27
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
253–535(283 aa)
Fragment:Src kinase domain
|
Mutation:S344N, A369S, Y418W
|
P01 2-({6-[(3-CHLOROPHENYL)AMINO]-9-ISOPROPYL-9H-PURIN-2-YL}AMINO)-3-METHYLBUTAN-1-OL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;297 K;20% ethylene glycol , pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 297K
|
Resolution 2.90 Å
R-free 0.313
|
|
2BDF
Src kinase in complex with inhibitor AP23451
Deposited 2005-10-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
257–535(279 aa)
Fragment:kinase domain
|
Not recorded
|
24A {[(4-{[2-(4-AMINOCYCLOHEXYL)-9-ETHYL-9H-PURIN-6-YL]AMINO}PHENYL)(HYDROXY)PHOSPHORYL]METHYL}PHOSPHONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;15% PEG400, 50mM NaCl, 100mM HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.271
|
|
2BDF
Src kinase in complex with inhibitor AP23451
Deposited 2005-10-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
257–535(279 aa)
Fragment:kinase domain
|
Not recorded
|
24A {[(4-{[2-(4-AMINOCYCLOHEXYL)-9-ETHYL-9H-PURIN-6-YL]AMINO}PHENYL)(HYDROXY)PHOSPHORYL]METHYL}PHOSPHONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;15% PEG400, 50mM NaCl, 100mM HEPES pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.271
|
|
2BDJ
Src kinase in complex with inhibitor AP23464
Deposited 2005-10-20
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
257–535(279 aa)
Fragment:kinase domain
|
Not recorded
|
HET 3-[2-(2-CYCLOPENTYL-6-{[4-(DIMETHYLPHOSPHORYL)PHENYL]AMINO}-9H-PURIN-9-YL)ETHYL]PHENOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.3;298 K;20% PEG3350, 200mM NH4NO3, pH 6.3, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.50 Å
R-free 0.277
|
|
2H8H
Src kinase in complex with a quinazoline inhibitor
Deposited 2006-06-07
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–535(535 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
H8H N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-7-[2-(4-METHYLPIPERAZIN-1-YL)ETHOXY]-5-(TETRAHYDRO-2H-PYRAN-4-YLOXY)QUINAZOLIN-4-AMINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 6.5;288 K;50 mM PIPES pH 6.5, 10 mM DTT, 100 mM sodium chloride and 4 to 9% PEG4000 (w/v), VAPOR DIFFUSION, SITTING DROP, temperature 288K
|
Resolution 2.20 Å
R-free 0.272
|
|
2SRC
CRYSTAL STRUCTURE OF HUMAN TYROSINE-PROTEIN KINASE C-SRC, IN COMPLEX WITH AMP-PNP
Deposited 1998-12-29
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
85–535(451 aa)
Fragment:RESIDUES 86-836, CONTAINING SH2, SH3, KINASE 2 DOMAINS AND C-TERMINAL TAIL
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
ANP PHOSPHOAMINOPHOSPHONIC ACID-ADENYLATE ESTER × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 6.5;pH 6.5
|
Resolution 1.50 Å
R-free 0.281
|
|
3ZMP
Src-derived peptide inhibitor complex of PTP1B
Deposited 2013-02-12
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain D
527–536(10 aa)
Fragment:RESIDUES 527-536
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2M MGCL2, 27.14W/V% PEG3350, 0.1M HEPES, PH=7.5
|
Resolution 2.62 Å
R-free 0.271
|
|
3ZMP
Src-derived peptide inhibitor complex of PTP1B
Deposited 2013-02-12
|
Different construct
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
527–536(10 aa)
Fragment:RESIDUES 527-536
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2M MGCL2, 27.14W/V% PEG3350, 0.1M HEPES, PH=7.5
|
Resolution 2.62 Å
R-free 0.271
|
|
3ZMQ
Src-derived mutant peptide inhibitor complex of PTP1B
Deposited 2013-02-12
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain C
527–536(10 aa)
Fragment:PROTO-ONCOGENE TYROSINE-PROTEIN KINASE SRC RESIDUES 527-536
|
Mutation:YES
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
0.2M MGCL2, 0.1M TRIS-HCL, PH=8.5 30% (W/V)POLYETHYLENE GLYCOL 4000
|
Resolution 3.30 Å
R-free 0.304
|
|
4F59
Triple mutant Src SH2 domain
Deposited 2012-05-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–252(109 aa)
Fragment:SH2 domain
|
Mutation:T183V/C188A/K206L
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.6;277 K;0.1 M Tris-HCl, 18% PEG6000, 0.2 M lithium chloride, pH 7.6, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.71 Å
R-free 0.246
|
|
4F5A
Triple mutant Src SH2 domain bound to phosphate ion
Deposited 2012-05-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–252(109 aa)
Fragment:SH2 domain
|
Mutation:T183V/C188A/K206L
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.6;277 K;0.1 M Tris-HCl, 18% PEG6000, 0.2 M lithium chloride, pH 7.6, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.80 Å
R-free 0.245
|
|
4F5B
Triple mutant Src SH2 domain bound to phosphotyrosine
Deposited 2012-05-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
144–252(109 aa)
Fragment:SH2 domain
|
Mutation:T183V/C188A/K206L
|
PTR O-PHOSPHOTYROSINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.6;277 K;0.1 M Tris-HCl, 18% PEG6000, 0.2 M lithium chloride, pH 7.6, vapor diffusion, sitting drop, temperature 277K
|
Resolution 1.57 Å
R-free 0.230
|
|
4HXJ
Crystal structure of SH3:RGT complex
Deposited 2012-11-11
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
87–144(58 aa)
Fragment:human c-Src SH3 domain, UNP residues 87-144
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;100mM Tris, pH 8.0, 1.3M sodium citrate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.193
|
|
4HXJ
Crystal structure of SH3:RGT complex
Deposited 2012-11-11
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
87–144(58 aa)
Fragment:human c-Src SH3 domain, UNP residues 87-144
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 8;298 K;100mM Tris, pH 8.0, 1.3M sodium citrate, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.00 Å
R-free 0.193
|
|
4K11
The structure of 1NA in complex with Src T338G
Deposited 2013-04-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
87–534(448 aa)
Fragment:UNP residues 87-534
|
Mutation:T338G
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
0J9 1-tert-butyl-3-(naphthalen-1-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;295 K;50 mM PIPES, pH 6.5, 12% PEG4000, 10 mM DTT, VAPOR DIFFUSION, HANGING DROP, temperature 295K
|
Resolution 2.30 Å
R-free 0.246
|
|
4MXO
human Src kinase bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Not recorded
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.254
|
|
4MXO
human Src kinase bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Not recorded
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.10 Å
R-free 0.254
|
|
4MXX
Human Src A403T mutant bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Mutation:A403T
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M Ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.60 Å
R-free 0.276
|
|
4MXX
Human Src A403T mutant bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Mutation:A403T
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M Ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.60 Å
R-free 0.276
|
|
4MXY
Src M314L T338M double mutant bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Mutation:M314L T338M
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å
R-free 0.266
|
|
4MXY
Src M314L T338M double mutant bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Mutation:M314L T338M
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å
R-free 0.266
|
|
4MXZ
Src M314L T338M double mutant bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Mutation:M314L, T338M
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å
R-free 0.266
|
|
4MXZ
Src M314L T338M double mutant bound to kinase inhibitor bosutinib
Deposited 2013-09-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
254–536(283 aa)
Fragment:Kinase domain, UNP residues 254-536
|
Mutation:M314L, T338M
|
DB8 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;298 K;0-4% PEG 3350, 0.2M ammonium acetate, 0.1M Hepes pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 298K
|
Resolution 2.58 Å
R-free 0.266
|
|
6ATE
SRC kinase bound to covalent inhibitor
Deposited 2017-08-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
|
Not recorded
|
6H3 N-{2-[(5-chloro-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;0.1 M MES, pH 6.5, 16%-20% PEG 3350, 350 mM - 420mM NaOAc
|
Resolution 2.40 Å
R-free 0.228
|
|
6C4S
Human cSrc SH3 Domain in complex with Choline Kinase fragment 60-69
Deposited 2018-01-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
87–144(58 aa)
Fragment:SH3 domain residues 87-144
Chain B
87–144(58 aa)
Fragment:SH3 domain residues 87-144
|
Not recorded
|
ZN ZINC ION × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;298 K;0.2 M Zinc Acetate
0.1 M Sodium Cacodylate pH 6.5
10% v/v Isopropanol
|
Resolution 1.50 Å
R-free 0.226
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain D
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 5
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain E
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 6
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain F
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 7
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain G
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
6E6E
DGY-06-116, a novel and selective covalent inhibitor of SRC kinase
Deposited 2018-07-24
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 8
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain H
261–536(276 aa)
|
Not recorded
|
HVY N-(2-chloro-6-methylphenyl)-2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4-{[2-(propanoylamino)phenyl]amino}pyrimidine-5-carboxamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;293 K;0.1M Magnesium Formate Dihydrate; 15% PEG3350
|
Resolution 2.15 Å
R-free 0.285
|
|
7NG7
Src kinase bound to eCF506 trapped in inactive conformation
Deposited 2021-02-08
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
|
Not recorded
|
EDO 1,2-ETHANEDIOL × 1
UCW tert-butyl (4-(4-amino-1-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-1H-pyrazolo[3,4-d]pyrimidin-3-yl)-2-methoxyphenyl)carbamate × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;6% PEG3350, 300mM Ammonium acetate, 0.1M HEPES pH7.5, 10mM TCEP
|
Resolution 1.50 Å
R-free 0.213
|
|
7OTE
Src Kinase Domain in complex with ponatinib
Deposited 2021-06-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
254–536(283 aa)
|
Not recorded
|
0LI 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide × 1
TRS 2-AMINO-2-HYDROXYMETHYL-PROPANE-1,3-DIOL × 1
GOL GLYCEROL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8;293 K;Tris 20 mM pH 8, 150 mM Sodium chloride, 1 mM DTT, 2-propanol and PEG 4.000
|
Resolution 2.49 Å
R-free 0.252
|
|
7OTE
Src Kinase Domain in complex with ponatinib
Deposited 2021-06-10
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
254–536(283 aa)
|
Not recorded
|
0LI 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzam ide × 1
GOL GLYCEROL × 6
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 8;293 K;Tris 20 mM pH 8, 150 mM Sodium chloride, 1 mM DTT, 2-propanol and PEG 4.000
|
Resolution 2.49 Å
R-free 0.252
|
|
7T1U
Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphopeptide
Deposited 2021-12-02
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain A
147–251(105 aa)
Fragment:SH2 domain
|
Mutation:Residues 180 to 188 mutated from SETTKGAYC to GQSQPDYV and K206I (numbered as residue 205 in these coordinates)
|
ZN ZINC ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;293 K;80 uM Zinc Acetate, 12% PEG3350, 100 mM Sodium Acetate (pH 4.0), and 2% 1,3-butanediol
|
Resolution 2.65 Å
R-free 0.270
|
|
7T1U
Crystal structure of a superbinder Src SH2 domain (sSrcF) in complex with a high affinity phosphopeptide
Deposited 2021-12-02
|
Different construct
Different mutation/modification
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein heterocomplex
Heteromer;Protein × 2
PDB declaration: dimeric
|
Chain B
147–251(105 aa)
Fragment:SH2 domain
|
Mutation:Residues 180 to 188 mutated from SETTKGAYC to GQSQPDYV and K206I (numbered as residue 205 in these coordinates)
|
ZN ZINC ION × 3
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 4;293 K;80 uM Zinc Acetate, 12% PEG3350, 100 mM Sodium Acetate (pH 4.0), and 2% 1,3-butanediol
|
Resolution 2.65 Å
R-free 0.270
|
|
7YQE
Structure of human SRC regulatory domains in complex with the C-terminal PRRP motifs of GPR54.
Deposited 2022-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
85–247(163 aa)
|
Mutation:C338S,C340S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;1% v/v 1,4 Dioxane, 0.1 M Tris pH 7.5, 12.5% w/v Polyethylene glycol 3,350
|
Resolution 3.50 Å
R-free 0.295
|
|
7YQE
Structure of human SRC regulatory domains in complex with the C-terminal PRRP motifs of GPR54.
Deposited 2022-08-06
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Insufficient information
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
85–247(163 aa)
|
Mutation:C338S,C340S
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;1% v/v 1,4 Dioxane, 0.1 M Tris pH 7.5, 12.5% w/v Polyethylene glycol 3,350
|
Resolution 3.50 Å
R-free 0.295
|
|
8HAQ
The complex of Src with GW8510
Deposited 2022-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
266–542(277 aa)
|
Not recorded
|
L1N 4-[(~{E})-(7-oxidanyl-6~{H}-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-~{N}-pyridin-2-yl-benzenesulfonamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M MOPS pH 7.0, 18% PEG 3350, 5% Glycerol, 5 mM TCEP
|
Resolution 2.27 Å
R-free 0.250
|
|
8HAQ
The complex of Src with GW8510
Deposited 2022-10-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
266–542(277 aa)
|
Not recorded
|
L1N 4-[(~{E})-(7-oxidanyl-6~{H}-pyrrolo[2,3-g][1,3]benzothiazol-8-yl)methylideneamino]-~{N}-pyridin-2-yl-benzenesulfonamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.1 M MOPS pH 7.0, 18% PEG 3350, 5% Glycerol, 5 mM TCEP
|
Resolution 2.27 Å
R-free 0.250
|
|
8JF3
C-Src in complex with compound 9
Deposited 2023-05-17
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
254–536(283 aa)
Chain B
254–536(283 aa)
|
Not recorded
|
C0N 2-[4-[4-[bis(oxidanylidene)-$l^5-sulfanyl]oxyphenyl]carbonylpiperazin-1-yl]-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-prop-2-ynyl-pyrimidine-4-carboxamide × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 6.5;293 K;300 mM Sodium Acetate, 0.1 M MES pH 7.5, 4% PEG3350
|
Resolution 2.85 Å
R-free 0.317
|
|
8JN8
Crystal structure of c-Src in complex with covalent inhibitor DC-Srci-6668
Deposited 2023-06-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–536(536 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
JA6 (2R)-N-cyclopentyl-2-[cyclopropyl(ethanoyl)amino]-2-(4-fluorophenyl)ethanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;289 K;0.2M tri-Lithium citrate, 20%(w/v) PEG 3350
|
Resolution 1.90 Å
R-free 0.254
|
|
8JN9
Crystal structure of c-Src in complex with covalent inhibitor LW-Srci-8
Deposited 2023-06-06
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
1–536(536 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
UJ0 N-[(1R)-1-[3,5-bis(fluoranyl)phenyl]-2-(cyclopentylamino)-2-oxidanylidene-ethyl]-N-cyclopropyl-prop-2-enamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;289 K;0.2M tri-Lithium citrate, 20%(w/v) PEG 3350
|
Resolution 2.72 Å
R-free 0.279
|
|
8VCF
Crystal structure of Superbinder Src SH2 domain with Cysteine to Serine mutations
Deposited 2023-12-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
161–268(108 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;pH 7.5;290 K;VAPOR DIFFUSION,SITTING DROP, TEMPERATURE 290K
0.2 M Ammonium Fluoride, 20% PEG 3350
|
Resolution 1.50 Å
R-free 0.177
|
|
8VCG
Mutant Src SH2 domain in complex with phosphotyrosine
Deposited 2023-12-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
161–267(107 aa)
Fragment:SH2 DOMAIN
|
Not recorded
|
PTR O-PHOSPHOTYROSINE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;290 K;VAPOR DIFFUSION,
SITTING DROP, TEMPERATURE 290K
0.2 M Ammonium Fluoride, 20% PEG 3350
|
Resolution 1.61 Å
R-free 0.176
|
|
9IRL
Crystal structure analysis of LW-Srci-2o in complex with c-Src.
Deposited 2024-07-16
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
86–536(451 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
A1L20 (2~{R})-2-[3,5-bis(fluoranyl)phenyl]-2-[2-chloranylethanoyl(cyclopropyl)amino]-~{N}-cyclopentyl-ethanamide × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;289 K;PEG 3350, Hepes 7.4
|
Resolution 2.03 Å
R-free 0.243
|
|
9NS0
Ground state of Src kinase domain
Deposited 2025-03-14
|
Different construct
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
251–536(286 aa)
|
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;298 K;Ionic strength (raw mmCIF value) 500;Pressure 1
NMR sample composition
250 uM [U-15N; U-2H] ILVMAT CH3 FY CEHE Proto-oncogene tyrosine-protein kinase Src, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
250 uM [U-13C; U-15N; U-2H] Proto-oncogene tyrosine-protein kinase Src, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
9NS1
Intermediate state of Src kinase domain
Deposited 2025-03-15
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
251–536(286 aa)
|
Not recorded
|
No recorded non-water small molecule
|
SOLUTION NMR
NMR measurement conditions
pH 6.5;303 K;Ionic strength (raw mmCIF value) 500;Pressure 1
NMR sample composition
250 uM [U-13C; U-15N; U-2H] SrcA311I kinase, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
NMR sample composition
250 uM [U-15N; U-2H] ILVMAT CH3 FY CEHE SrcA311I kinase, 25 mM potassium chloride, 500 mM sodium chloride, 3 mM BME, 1 mM EDTA, 90% H2O/10% D2O | 90% H2O/10% D2O
|
Resolution not provided
|
|
9OFX
Crystal structure of c-Src SH3 domain in H32 space group mediated by nickel
Deposited 2025-04-30
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 4
PDB declaration: tetrameric
|
Chain A
85–143(59 aa)
Fragment:c-Src SH3 domain
Chain B
85–143(59 aa)
Fragment:c-Src SH3 domain
Chain C
85–143(59 aa)
Fragment:c-Src SH3 domain
Chain D
85–143(59 aa)
Fragment:c-Src SH3 domain
|
Not recorded
|
NI NICKEL (II) ION × 2
GOL GLYCEROL × 9
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;293 K;1.7 M Ammonium Sulfate, 5 mM NiCl2, 10% glycerol, 0.1 M HEPES pH 7.5
|
Resolution 1.45 Å
R-free 0.196
|